聚焦艾昆纬-加速访问和早期证据:15年PBAC提交的经验教训(英)-2026。iqvia.com | 1 Executive summary Between 2010 and 2025, only 3.8% of PBAC submissions relied on early-phase clinical trial data, yet these achieved notable success when supported by robust evidence and high unmet needs.Activity increased from 2016 onward, peaking during 2020–2023 amid global shifts toward accelerated access.
聚焦艾昆纬-加速访问和早期证据:15年PBAC提交的经验教训(英)-2026。iqvia.com | 1 Executive summary Between 2010 and 2025, only 3.8% of PBAC submissions relied on early-phase clinical trial data, yet these achieved notable success when supported by robust evidence and high unmet needs.Activity increased from 2016 onward, peaking during 2020–2023 amid global shifts toward accelerated access.
聚焦艾昆纬-加速访问和早期证据:15年PBAC提交的经验教训(英)-2026。iqvia.com | 1 Executive summary Between 2010 and 2025, only 3.8% of PBAC submissions relied on early-phase clinical trial data, yet these achieved notable success when supported by robust evidence and high unmet needs.Activity increased from 2016 onward, peaking during 2020–2023 amid global shifts toward accelerated access.
覆盖 2026 年,全文约 9。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
重点分析了艾昆纬、加速访问和早期证据、15年PBAC提交的经验教训等议题。